Log in
Pharmacology · Drugs Acting on Adrenergic Synapses

Guanethidine

*Guanethidinum*

Guanethidine is a sympatholytic that lowers blood pressure by depleting norepinephrine stores in sympathetic nerve endings. Unlike reserpine, the drug does not cross into the brain, but it causes pronounced orthostatic hypotension, which limits its use.

MechanismDisplacement of norepinephrine from sympathetic vesicles
Peak effectDevelops slowly, peaking on days 7–8 of treatment
Dangerous effectSevere orthostatic hypotension
CNSDoes not cross the blood-brain barrier, does not cause depression
4 min readFor medical studentsUpdated 09/24/2026
Material prepared by WhiteCoat Pro editorial team based on platform study guidesReviewed by medical editor: Aulov A. A., general practitioner · 09/24/2026

Mechanism of action at the cellular level

Guanethidine acts exclusively at the terminals of sympathetic nerve fibers. Its mechanism of action is fundamentally different from reserpine and relies on "tricking" the neuron's transport systems. The process occurs in several stages:

  1. Terminal uptake. Guanethidine actively competes with the physiological neurotransmitter, norepinephrine, for neuronal reuptake systems. As a result, the drug molecules themselves are taken up by the sympathetic fiber.
  2. Vesicular entry. Once inside the cell, guanethidine enters synaptic vesicles (where the neurotransmitter is stored) and physically displaces norepinephrine from them.
  3. Neurotransmitter degradation. Norepinephrine ejected from the vesicles into the cytoplasm does not reach the synaptic cleft—it is rapidly degraded by the intracellular enzyme monoamine oxidase (MAO).
  4. Blockade of synthesis and release. Having secured its place in the vesicles, guanethidine not only blocks the enzymatic synthesis of new norepinephrine from dopamine, but also directly inhibits exocytosis—the process of neurotransmitter release.

The ultimate result of these cellular processes is profound depletion of norepinephrine stores.

Pharmacodynamics and hemodynamic effects

The main clinical target of guanethidine is the cardiovascular system. As neurotransmitter stores become depleted, a marked decrease in sympathetic tone occurs. Blood pressure drops through two parallel mechanisms:

  • Total peripheral resistance (TPR) decreases due to vasodilation.
  • Cardiac output decreases.

Pharmacokinetic features: The drug is characterized by a long latent period. Time is required for norepinephrine stores to deplete to a level that affects blood pressure. The maximum hypotensive effect unfolds only on days 7–8 of continuous therapy. After complete withdrawal of guanethidine, the aftereffect persists for up to two weeks, until sympathetic endings restore their neurotransmitter pool.

Test your knowledge on the topicTasks from the «Pharmacology» course bank — instant answers and explanations.

Side effects and comparison with reserpine

The safety profile of guanethidine has distinct features determined by both the specifics of its action and compensatory reactions of the autonomic nervous system.

Differences from reserpine (advantages):

  • Brain sparing. Guanethidine is completely incapable of crossing the blood-brain barrier (BBB). It does not cause drug-induced depression, sedation, or lethargy.
  • Adrenal sparing. The drug does not affect the secretion of catecholamines by adrenal medullary cells. This is because the adrenal medulla lacks the membrane neuronal reuptake systems that are critically required for guanethidine to enter the cell.

Specific hazard: A key drawback of guanethidine that distinguishes it from reserpine is the development of severe orthostatic hypotension. When a patient abruptly transitions from a supine to an upright position, blood vessels lacking sympathetic control are unable to constrict rapidly, leading to a critical drop in blood pressure.

Symptoms of parasympathetic predominance: As with reserpine, blockade of the sympathetic system leads to dominance of parasympathetic tone. Clinically, this manifests as pronounced bradycardia, persistent nasal congestion, and GI stimulation (increased glandular secretion, diarrhea).

Current status in clinical practice

Due to the high risk of severe orthostatic reactions and the availability of safer antihypertensive drugs, guanethidine is currently practically excluded from routine clinical practice. Its main niche today is experimental research (e.g., pharmacological modeling of chemical sympathectomy in laboratory animals).

Briefly: answers to topical questions

With which drug classes does guanethidine engage in clinically significant interactions or exhibit antagonism?

Guanethidine is mentioned among sympatholytics involved in pharmacodynamic interactions at the level of the mechanism of action. Such interactions are described for drugs affecting the adrenergic system: with simultaneous use of stimulants and adrenergic receptor blockers, adrenergic receptor blockers such as phentolamine and propranolol reduce or eliminate the effects of stimulants such as norepinephrine and isoprenaline.

How to memorize

G — Guanethidine: Hypotension (orthostatic is present), but Head is clear (does not cross the BBB, no depression).

Class and exam questions

Why does the hypotensive effect develop so slowly with guanethidine?

The drug does not block receptors directly, but gradually displaces norepinephrine from nerve terminal vesicles. It takes several days for neurotransmitter stores to deplete enough to lower sympathetic tone, which is why the peak effect occurs by days 7–8.

What causes nasal congestion and diarrhea during drug administration?

When the sympathetic nervous system is pharmacologically shut down, the parasympathetic system (vagus nerve) begins to dominate compensatorily. This leads to dilation of nasal mucosal vessels, increased secretion of digestive glands, and enhanced intestinal motility.

Does guanethidine affect adrenaline release by the adrenal glands?

No, it does not affect it. To penetrate inside the cell, guanethidine requires a specific neuronal reuptake mechanism, which is present only in synapses and completely absent in adrenal medullary cells.

Something unclear? Ask the AIThe AI tutor has reviewed the material on "Guanethidine" and will explain it in simple terms.

What else to study on this topic

  • Molecular structure and functions of neuronal reuptake systems (NET)
  • The role of the enzyme monoamine oxidase (MAO) in catecholamine metabolism
  • Pathophysiology and hemodynamic shifts in orthostatic hypotension
  • Comparative characteristics of sympatholytics: guanethidine, reserpine, bretylium
  • Mechanisms of norepinephrine synthesis from dopamine inside synaptic vesicles

Master the entire topic in the «Pharmacology» course

This is a summary. The course covers everything tested in classes and exams.

  • Complete study guide on "Guanethidine" and 5,304 other pages of the subject
  • Assignments and quizzes after every topic — just like in a colloquium
  • AI tutor answers questions on the topic anytime
  • 116 video lessons on the subject

Other topics in the section "Drugs Acting on Adrenergic Synapses"

Entire section "Drugs Acting on Adrenergic Synapses"

Free video lessons: pharmacologyShort lessons with study notes — no registration required.

Watch lessons

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.